TP0903 represents another AXL inhibitor that has had efficacy against AML in preclinical studies and specifically demonstrated the ability to resensitize FLT3 inhibitor-resistant cells (Fig. 3).144 TP0903 also has demonstrated activity against CLL and was started in a phase I clinical trial to determine safety and efficacy both as a monotherapy and in combination with ibrutinib in patients with CLL and small lymphocytic lymphoma. This evidence concerns the gene AXL and acute myeloid leukemia.